Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AbbVie, FDA and Parkinson's Disease
AbbVie says latest FDA approval expands Botox use beyond face
Botox Cosmetic expands beyond face for the first time as FDA approves the anti-wrinkle therapy for treating platysma bands. Read more here.
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease (PD). The drug will be marketed under the trade name Vyalev.
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
The FDA approved AbbVie's Vyalev as the first 24-hour subcutaneous infusion therapy for advanced Parkinson's disease, offering improved motor control and reduced symptoms. Approval was based on a pivotal Phase 3 study.
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopais now authorized by the U.S. Food and Drug Administration, AbbVie ( ABBV, Financials) said Thursday.
AbbVie’s Vyalev receives US FDA approval to treat adults living with advanced Parkinson's disease
North Chicago, Illinois Saturday, October 19, 2024, 12:00 Hrs [IST]
1d
on MSN
Analysts revise AbbVie stock price target ahead of earnings
Related: Analyst revises AbbVie stock price target on drug-sale estimates Sales eroded, however, as Humira faced competition ...
2d
on MSN
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
Crain's Chicago Business
2d
New AbbVie Parkinson’s drug finally gets green light to hit U.S. market
After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...
24/7 Wall St
4d
Dividend Aristocrat AbbVie Just Paid Investors; Here's How Much They Received
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.
1d
AbbVie price target raised to $220 from $214 at BMO Capital
BMO Capital raised the firm’s price target on AbbVie to $220 from $214 and keeps an Outperform rating on the shares as part ...
Crain's Chicago Business
5d
AbbVie tries to fast-track new cancer drug for approval to join 2 others in its pipeline
There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...
bovnews
1d
AbbVie Inc (ABBV) Posted 9.63% Profit Margin Last Year—Can It Hold Up?
On Thursday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $188.57 which represents a decrease of $-1.89 or -0.99% from the prior close of $190.46. The stock opened at $190.54 and touched a ...
1d
IQ EQ FUND MANAGEMENT IRELAND Ltd Cuts Stock Holdings in AbbVie Inc. (NYSE:ABBV)
IQ EQ FUND MANAGEMENT IRELAND Ltd lessened its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 3.0% during the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
vyalev
United States
New York Stock Exchange
Parkinson's disease
Calendar year
Feedback